Oncology Venture now holds US Orphan Drug designation on dovitinib for Adenoid Cystic Carcinoma
Hoersholm, Denmark, June 28, 2018 – Oncology Venture AB (OV:ST) and Medical Prognosis Institute A/S (MPI:ST) announces that the Office of Orphan Products Development at the FDA has transferred the Dovitinib Orphan drug designation for the treatment of adenoid cystic carcinoma to Oncology Venture from Novartis.Dovitinib is an oral available phase 3 multi Tyrosine Kinase Inhibitor (previously TKI258), for which OV holds the exclusive global rights for development and commercialization. OV is developing the dovitinib Drug Response predictor DRP® based on existing data from patient’s biopsies